Antibiotic Breakpoints: How Redefining Susceptibility Preserves Efficacy and Improves Patient Care

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacokinetics/Pharmacodynamics

Background:

• Carbapenems represent a critical therapeutic class for managing infections caused by multidrug-resistant bacterial pathogens.
• The increasing prevalence of antimicrobial resistance necessitates careful monitoring and strategic use of carbapenems.
• Maintaining the clinical utility of carbapenems is essential for public health.

Purpose of the Study:

• To emphasize the importance of clinical breakpoints for carbapenems.
• To ensure that recommended dosing regimens achieve adequate pharmacokinetic/pharmacodynamic (PK/PD) targets.
• To guide strategies for antimicrobial stewardship and resistance containment.

Main Methods:

• This study focuses on the principles of pharmacokinetic/pharmacodynamic (PK/PD) target attainment.
• Analysis of existing data and literature regarding carbapenem efficacy and resistance.
• Review of current guidelines for antimicrobial susceptibility testing and breakpoint setting.

Main Results:

• Clinical breakpoints directly influence the probability of achieving desired PK/PD targets.
• Inadequate breakpoints can lead to under-dosing and contribute to treatment failure.
• Appropriate breakpoints are essential for distinguishing susceptible from resistant isolates.

Conclusions:

• Setting appropriate carbapenem breakpoints is paramount for effective treatment of multidrug-resistant infections.
• Optimized breakpoints are key to preserving the efficacy of carbapenems and combating resistance.
• Continued research and surveillance are necessary to refine breakpoint guidelines.